A revolutionary class of asthma therapeutics
RaeSedo, Inc.
You know someone with asthma
Asthma is the most common and potentially deadly respiratory disease in the world that affects ~10% of the population.
Asthma patients live every day with shortness of breath, wheezing and cough. Asthma affects 20 million people in the US alone and accounts for ~400,000 deaths per year.
Asthma is on the rise, increasing by 19% in the US since 2001. Most people know someone with asthma but what might not be apparent is that can be very severe for a subset of patients with asthma. These patients experience wheezing, cough and shortness of breath every day seriously affects their ability to work, or go to school.Asthma attacks, where these symptoms become so severe that additional medical care is needed like hospitalization or an emergency department visit, create a huge burden for our patients with severe asthma and a cost of close to $82 billion in health care expenditures and lost productivity.
Despite advances in the understanding of the immunology of asthma with improved medications and now biologics that target specific inflammatory pathways, we have not come close to eliminating asthma attacks.
Therefore, there is a critical need to develop better therapeutics to target the underlying inflammation while also controlling asthma symptoms across all types of asthma.
SP-A derived small peptide theraputic
SP-A Therapeutics For Asthma
Within the lungs, surfactant protein-A (SP-A) is a naturally occurring protein that is the first line of defense when encountering viral, allergen, or environmental irritants.
We have identified a 10-20 amino acid sequence that can reproduce the activity of full-length SP-A in reducing inflammation, mucus and airway constriction associated with asthma.
Our goal is to develop a replacement therapy using this novel endogenous protein.
Our Team
The approaches for RaeSedo, Inc. started with the patient where gaps in asthma therapeutics were identified, coupled with data using genomics, human cells and animal models demonstrating that surfactant protein has anti-inflammatory effects relevant to asthma.
Julie Ledford, PhD
Dr. Ledford is an expert in the role of endogenous lung proteins and mechanisms through which they mediate various states of lung inflammation, pathogen infection and lung disease progression using pre-clinical animal models.
Monica Kraft, MD
Dr. Kraft is a is a world-renowned physician-scientist with over 150 publications in the areas of adult asthma, the role of infection in asthma and the role of the distal lung in asthma and airway remodeling.
Jan Mark Creidenberg
Mr. Creidenberg is a business leader with 35+ years’ of experience in pharmaceuticals, medical device, strategic consulting and private equity. As CEO he provides business and strategic leadership as part of the RaeSedo team.
Jody Yarbrough, MBA
Ms. Yarbrough is a finance and accounting professional with 25+ years’ experience in healthcare. As a consulting CFO, she supports private sector business helping solve their operational and financial business challenges.